Page 6 - Beyondspring Inc News Today

Under the priority review, the target action date is set for November 30. Plinabulin acts as a selective immunomodulating microtubule-binding agent (SIMBA), with immune anti-cancer activities and broad activities to prevent CIN across chemotherapy and cancer types. Price Action: BYSI shares are up 11.4% at $11.55 during the market session on the last check Tuesday. © 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.   Related Articles (BYSI)

Home / Top News / BeyondSpring Announces Submission of New Drug Application to U.S. FDA and China NMPA for Plinabulin and G-CSF Combination for the Prevention of Chemotherapy-Induced Neutropenia (CIN) BeyondSpring Announces Submission of New Drug Application to U.S. FDA and China NMPA for Plinabulin and G-CSF Combination for the Prevention of Chemotherapy-Induced Neutropenia (CIN) – Applications are supported by positive PROTECTIVE-2 Phase 3 data demonstrating that plinabulin in combination w...

BeyondSpring Inc (NASDAQ: BYSI) has submitted marketing applications in the U.S. and China seeking approval for plinabulin in ...

BRIEF-Beyondspring Announces Submission Of New Drug Application To U.S. FDA And China NMPA For Plinabulin And G-CSF Combination Reuters 1 hr ago March 31 (Reuters) - Beyondspring Inc: * BEYONDSPRING ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION TO U.S. FDA AND CHINA NMPA FOR PLINABULIN AND G-CSF COMBINATION FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NEUTROPENIA (CIN) * NDA SUBMISSION IS BASED ON POSITIVE DATA FROM BEYONDSPRINGS PROTECTIVE-2 PHASE 3 REGISTRATION STUDY * BEYONDSPRING - STUDY MET...